Day: June 16, 2021

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Brooke Story to its Board of Directors. “I am delighted to welcome Brooke to our Board,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “Brooke’s extensive commercial and operating expertise will be valuable as we advance our non-viral engineered cell-based therapies through the clinic. We look forward to her insights and contributions as we work together to bring functional cures to patients with a wide range of chronic diseases.” Ms. Story currently serves as President of BD Integrated Diagnostic Solutions, where she is responsible for driving global strategic,...

NFI BYD ADL Enviro400EVNFI BYD ADL Enviro400EV battery electric busVehicles support Transport for London’s commitment to an emission free bus fleet WINNIPEG, Manitoba, June 16, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that the BYD UK and Alexander Dennis Limited (“ADL”) electric vehicle partnership, the UK’s leading electric bus producer, will deliver the UK’s largest ever electric bus order. The order has been placed by RATP Dev London, one of Transport for London (“TfL”)’s principal bus operators, for a total of 195 single and double deck vehicles. With this order, RATP Dev London confirms its commitment to supporting TfL’s electrification plan for London’s...

Milestone in the amount of $50 million realized BOSTON, June 16, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it has achieved a milestone associated with the development of AT-527 and expects to receive a related payment under its license agreement with Roche of $50 million (SIX: RO, ROG; OTCQX: RHHBY). Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19. Atea retains rights to commercialize AT-527 in the United States and Roche has the exclusive right to commercialize AT-527 outside of the United States. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from...

RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference. The fireside chat will take place on June 22nd at 9:20 AM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic...

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the Company plans to participate in the Raymond James 2021 Human Health Innovation Conference. CareDx’s management will be participating in the Raymond James 2021 Human Health Innovation Conference on Monday, June 21, 2021 at 10:40 a.m Eastern Time. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com. About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development...

TORONTO, June 16, 2021 (GLOBE NEWSWIRE) — Nobel29 Resources Corp. (TSX-V: NBLC) (the “Company” or “Nobel”) is pleased to announce that its submission of the Form 211 to FINRA has been cleared and the Company’s common shares now qualify for trading in the United States on the OTC Pink Market under the symbol “NBTRF”. Nobel has applied for DTC eligibility by the Depository Trust Company (“DTC”) for its shares traded on the OTC Pink Market and it expects to receive DTC’s approval in the coming weeks. “This is an exciting step forward for Nobel and its US based investors. We hope to receive DTC eligibility soon which will be the final step in ensuring that US based investors can more easily participate in our rapidly growing company,” commented David Gower, Nobel’s CEO. The DTC is a subsidiary of the Depository...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA CALGARY, Alberta, June 16, 2021 (GLOBE NEWSWIRE) — Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased to announce that, due to investor interest, it has closed an upsized, non-brokered private placement (the “Offering“). Pursuant to the Offering, the Company issued an aggregate of 20,799,200 common shares (the “Common Shares“) at a price of $0.25 per Common Share for gross proceeds of $5,199,800. After giving effect to the Offering, the Company will have 42,043,660 common shares issued and outstanding. The Corporation’s two significant shareholders and certain directors and officers participated in the Offering. On a combined basis they subscribed for an aggregate of 8,330,700 Common...

Katy, Texas, June 16, 2021 (GLOBE NEWSWIRE) — CW Petroleum Corp (OTCQB: CWPE), a leading provider of Proprietary Reformulated No Ethanol Gasoline and Biofuels, announce today forecasted Revenue for 6-Months Ending 6/31/2021 is projected to exceed 2020 Sales for the same fiscal period. The Company also identified a Capital Funding Group that will provide Capital for its Proprietary Reformulated No Ethanol Gasoline expansion in Texas and Northeastern United States via its current SEC approved Regulation 1-A offering. Regulation-A – Tier 2 Offering For additional information, visit our website at cwpetroleumcorp.com ,email: investor@cwpetroleumcorp.com , or call 281-817-8099 About CW Petroleum CorpCW Petroleum Corp supplies and distributes Biodiesel, Biodiesel Blends, Ultra Low Sulfur Diesel Fuel, Gasoline, and a Proprietary EPA Approved...

— Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel — RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older. The Israeli Ministry of Health also has granted an accelerated review. In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd., a corporation organized under the laws of the State of Israel, the exclusive rights to commercialize ORLADEYO in Israel.  “Neopharm is the right partner to help us commercialize in Israel as we continue to bring oral, once-daily ORLADEYO to HAE patients around...

— TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder The study is being conducted and funded by the National Institute on Drug Abuse (NIDA), part of the NIH — CHESTERBROOK, Pa., June 16, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that NIDA has resumed recruiting patients for its proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist. The Company has an ongoing collaboration with NIDA to evaluate TRV734 as a potential maintenance therapy for opioid use disorder (OUD). The study was paused in March 2020...